Tumor mutational burden (TMB) by next-generation sequencing is emerging as a biomarker of response to immunotherapy agents in cancer patients. However, heterogeneity in experimental and analytical protocols, as well as bioinformatic pipelines, influence the variability for TMB estimation and reporting, demonstrating the need for standardization and harmonization of TMB assessment methodology across assays and clinical centers. Friends of Cancer Research (Friends) and the Quality Assurance Initiative Pathology (QuIP), have collaborated to coordinate efforts for international multi-stakeholder initiatives to address this need.
TMB: The Case for Understanding and Harmonizing Complex Biomarkers
Albrecht Stenzinger, MD, University Hospital Heidelberg, Heidelberg, Germany
Objectives:
- Review TMB as a biomarker for immunotherapy response in cancer patients.
- Describe methodologies for TMB assessment and quantification.
- Review the many factors that influence TMB assessment
Duration: 0.75 hr
Recording Date: November 9, 2019
CME/CMLE credit: 0.75 hr
Last day to purchase course and CE claim credit: December 24, 2022
